50 Participants NeededMy employer runs this trial

Tirzepatide for Heart Failure and Obesity

JI
Overseen ByJessica Idumonyi
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: Columbia University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. In conjunction with state-of-the-art body composition analysis and measures of adipokines, this will establish an important mechanism of clinical benefit and inform disease pathophysiology. To accomplish this, this study will perform a 15-month prospective cohort study in 50 patients with obesity and HFpEF who clinically qualify for treatment with tirzepatide. The investigators will serially measure plasma volume and body composition with quantitative magnetic resonance to determine changes over time with tirzepatide treatment.

Who Is on the Research Team?

EA

Elissa A Driggin, MD

Principal Investigator

Columbia University

Are You a Good Fit for This Trial?

This trial is for adults with obesity (BMI over 30) and a specific type of heart failure called HFpEF, who have moderate symptoms and stable heart medications. Participants must meet certain heart function criteria based on recent tests.

Inclusion Criteria

I have been on stable heart failure medications and my fluid levels are well controlled.
* Left ventricular ejection fraction \>= 45% within 6 months of recruitment
* Body mass index (BMI) \>30 kg/m2
See 2 more

What Are the Treatments Tested in This Trial?

Interventions

  • Tirzepatide

Trial Overview

The study is testing tirzepatide, a medication given to people with both obesity and HFpEF, to see if it can reduce blood plasma volume and improve body composition over 15 months. About 50 participants will be closely monitored during the study.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: TirzepatideExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Columbia University

Lead Sponsor

Trials
1,529
Recruited
2,832,000+